Proteon ups Phase III PATENCY-2 enrollment

By Julian Zhu | May 12, 2017 | 8:36 PM GMT

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error